PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32899083-0 2020 Left atrial appendage thrombus formation in a patient with atrial fibrillation on dabigatran therapy associated with CES1 and ABCB1 genetic polymorphisms: A case report. Dabigatran 82-92 carboxylesterase 1 Homo sapiens 117-121 33179295-11 2021 The minor allele(A) on the CES1 SNP rs2244613 was associated with increased trough PDCs and higher risk for minor bleeding in NVAF patients treated with dabigatran. Dabigatran 153-163 carboxylesterase 1 Homo sapiens 27-31 33935512-0 2021 The Impact of ABCB1 and CES1 Polymorphisms on Dabigatran Pharmacokinetics in Healthy Chinese Subjects. Dabigatran 46-56 carboxylesterase 1 Homo sapiens 24-28 33935512-8 2021 CES1 rs8192935 were associated with the peak concentration of dabigatran. Dabigatran 62-72 carboxylesterase 1 Homo sapiens 0-4 33179295-0 2021 The impact of ABCB1 and CES1 polymorphisms on dabigatran pharmacokinetics and pharmacodynamics in patients with atrial fibrillation. Dabigatran 46-56 carboxylesterase 1 Homo sapiens 24-28 33179295-1 2021 AIMS: Our study aimed to determine the impact of genetic polymorphisms of ABCB1 and CES1 on the pharmacokinetics (PK) and pharmacodynamics (PD) of dabigatran in patients with non-valvular atrial fibrillation (NVAF). Dabigatran 147-157 carboxylesterase 1 Homo sapiens 84-88 33440670-5 2021 Most of the results presented here have a lot to do with some SNPs of CES1 (rs2244613, rs8192935, and rs71647871) and ABCB1 (rs1128503, rs2032582, rs1045642, and rs4148738) genes, and dabigatran, rivaroxaban, and apixaban. Dabigatran 184-194 carboxylesterase 1 Homo sapiens 70-74 32899083-3 2020 CES1 (carboxylesterase 1) and ABCB1 (ATP-binding cassette subfamily B member 1) genetic polymorphisms associate with the pharmacokinetics of dabigatran. Dabigatran 141-151 carboxylesterase 1 Homo sapiens 0-4 32899083-3 2020 CES1 (carboxylesterase 1) and ABCB1 (ATP-binding cassette subfamily B member 1) genetic polymorphisms associate with the pharmacokinetics of dabigatran. Dabigatran 141-151 carboxylesterase 1 Homo sapiens 6-24 32899083-10 2020 LESSONS: Multiple mutations in the ABCB1 and CES1 genes may influence the pharmacokinetics of dabigatran and could have contributed to the thrombus formation in the left atrial appendage. Dabigatran 94-104 carboxylesterase 1 Homo sapiens 45-49 31104266-7 2019 Metabolic clearances of dabigatran etexilate and dabigatran were implemented using data on carboxylesterase 1/2 enzymes and UGT subtype 2B15. Dabigatran 24-44 carboxylesterase 1 Homo sapiens 91-111 32564268-0 2020 Effect of Sex, Use of Pantoprazole and Polymorphisms in SLC22A1, ABCB1, CES1, CYP3A5 and CYP2D6 on the Pharmacokinetics and Safety of Dabigatran. Dabigatran 134-144 carboxylesterase 1 Homo sapiens 72-76 32134727-0 2020 Effect of CES1 and ABCB1 genotypes on the pharmacokinetics and clinical outcomes of dabigatran etexilate in patients with atrial fibrillation and chronic kidney disease. Dabigatran 84-104 carboxylesterase 1 Homo sapiens 10-14 32134727-11 2020 Conclusions Polymorphism of CES1 rs2244613 can contribute to the safety of dabigatran in patients with AF and CKD. Dabigatran 75-85 carboxylesterase 1 Homo sapiens 28-32 31104266-7 2019 Metabolic clearances of dabigatran etexilate and dabigatran were implemented using data on carboxylesterase 1/2 enzymes and UGT subtype 2B15. Dabigatran 24-34 carboxylesterase 1 Homo sapiens 91-111 27614009-11 2016 A personalized DABE treatment approach based on patient-specific CES1 genotypes and sex may have the potential to improve the efficacy and safety of DABE pharmacotherapy. Dabigatran 15-19 carboxylesterase 1 Homo sapiens 65-69 30658513-7 2019 CES1 and ABCB1 SNPs are the most common documented genetic variants that contribute to alteration in peak and trough levels of dabigatran with demonstrated clinical impact. Dabigatran 127-137 carboxylesterase 1 Homo sapiens 0-4 30850966-0 2019 Genetic determinants of dabigatran safety (CES1 gene rs2244613 polymorphism) in the Russian population: multi-ethnic analysis. Dabigatran 24-34 carboxylesterase 1 Homo sapiens 43-47 30850966-1 2019 This study was aimed to investigate the prevalence of the CES1 gene (c.1168-33A > C, rs2244613) polymorphism among 12 different ethnic groups living in Russia to provide a basis for future clinical studies concerning genetic determinants of dabigatran safety. Dabigatran 244-254 carboxylesterase 1 Homo sapiens 58-62 30100750-4 2018 The objectives of this study were to assess the effect of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) polymorphisms on dabigatran pharmacokinetics in patients after total knee arthroplasty. Dabigatran 128-138 carboxylesterase 1 Homo sapiens 94-98 29867495-6 2018 We firstly reported the documented case in a Chinese patient carrying multiple alleles of ABCB1 and CES-1, who suffered from thrombus in the left atrial appendage despite long-term anticoagulation with dabigatran. Dabigatran 202-212 carboxylesterase 1 Homo sapiens 100-105 29867495-7 2018 More clinical data are required to elucidate the impact of CES-1 and ABCB1 polymorphism on dabigatran pharmacokinetics, especially for Asian. Dabigatran 91-101 carboxylesterase 1 Homo sapiens 59-64 27614009-0 2016 Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender. Dabigatran 0-20 carboxylesterase 1 Homo sapiens 51-55 27614009-1 2016 The oral anticoagulant prodrug dabigatran etexilate (DABE) is sequentially metabolized by intestinal carboxylesterase 2 (CES2) and hepatic carboxylesterase 1 (CES1) to form its active metabolite dabigatran (DAB). Dabigatran 31-51 carboxylesterase 1 Homo sapiens 139-157 27614009-1 2016 The oral anticoagulant prodrug dabigatran etexilate (DABE) is sequentially metabolized by intestinal carboxylesterase 2 (CES2) and hepatic carboxylesterase 1 (CES1) to form its active metabolite dabigatran (DAB). Dabigatran 31-51 carboxylesterase 1 Homo sapiens 159-163 27614009-1 2016 The oral anticoagulant prodrug dabigatran etexilate (DABE) is sequentially metabolized by intestinal carboxylesterase 2 (CES2) and hepatic carboxylesterase 1 (CES1) to form its active metabolite dabigatran (DAB). Dabigatran 53-57 carboxylesterase 1 Homo sapiens 139-157 27614009-1 2016 The oral anticoagulant prodrug dabigatran etexilate (DABE) is sequentially metabolized by intestinal carboxylesterase 2 (CES2) and hepatic carboxylesterase 1 (CES1) to form its active metabolite dabigatran (DAB). Dabigatran 53-57 carboxylesterase 1 Homo sapiens 159-163 27614009-1 2016 The oral anticoagulant prodrug dabigatran etexilate (DABE) is sequentially metabolized by intestinal carboxylesterase 2 (CES2) and hepatic carboxylesterase 1 (CES1) to form its active metabolite dabigatran (DAB). Dabigatran 31-41 carboxylesterase 1 Homo sapiens 139-157 27614009-1 2016 The oral anticoagulant prodrug dabigatran etexilate (DABE) is sequentially metabolized by intestinal carboxylesterase 2 (CES2) and hepatic carboxylesterase 1 (CES1) to form its active metabolite dabigatran (DAB). Dabigatran 31-41 carboxylesterase 1 Homo sapiens 159-163 27614009-1 2016 The oral anticoagulant prodrug dabigatran etexilate (DABE) is sequentially metabolized by intestinal carboxylesterase 2 (CES2) and hepatic carboxylesterase 1 (CES1) to form its active metabolite dabigatran (DAB). Dabigatran 53-56 carboxylesterase 1 Homo sapiens 139-157 27614009-1 2016 The oral anticoagulant prodrug dabigatran etexilate (DABE) is sequentially metabolized by intestinal carboxylesterase 2 (CES2) and hepatic carboxylesterase 1 (CES1) to form its active metabolite dabigatran (DAB). Dabigatran 53-56 carboxylesterase 1 Homo sapiens 159-163 27614009-2 2016 A recent genome-wide association study reported that the CES1 single nucleotide polymorphisms (SNPs) rs2244613 and rs8192935 were associated with lower DAB plasma concentrations in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) study participants. Dabigatran 152-155 carboxylesterase 1 Homo sapiens 57-61 27614009-4 2016 The aim of this study was to examine the effect of CES1 genetic polymorphisms and gender on DABE activation using several in vitro approaches. Dabigatran 92-96 carboxylesterase 1 Homo sapiens 51-55 27614009-11 2016 A personalized DABE treatment approach based on patient-specific CES1 genotypes and sex may have the potential to improve the efficacy and safety of DABE pharmacotherapy. Dabigatran 149-153 carboxylesterase 1 Homo sapiens 65-69 24212377-4 2014 Experiments using expressed carboxylesterase 1 (CES1) and CES2 bactosomes revealed that dabigatran etexilate was hydrolyzed into BIBR 1087 by CES1 expressed in our Caco-2 cells. Dabigatran 88-108 carboxylesterase 1 Homo sapiens 28-46 27261537-3 2016 ABCB1 and CES1 exert an important effect in the metabolism of dabigatran etexilate and allele variants at these two loci are likely to play a pivotal role. Dabigatran 62-82 carboxylesterase 1 Homo sapiens 10-14 27261537-4 2016 To investigate whether screening for polymorphisms within the ABCB1 and the CES1 genes would explain a portion of the inter-individual variability in blood concentrations of the active metabolite of dabigatran. Dabigatran 199-209 carboxylesterase 1 Homo sapiens 76-80 27261537-10 2016 The CES1 SNP rs8192935 significantly influenced the dabigatran trough concentrations and carriers of the T allele showed significantly lower concentrations than did carriers of the CC genotype. Dabigatran 52-62 carboxylesterase 1 Homo sapiens 4-8 24212377-4 2014 Experiments using expressed carboxylesterase 1 (CES1) and CES2 bactosomes revealed that dabigatran etexilate was hydrolyzed into BIBR 1087 by CES1 expressed in our Caco-2 cells. Dabigatran 88-108 carboxylesterase 1 Homo sapiens 48-52 24212377-4 2014 Experiments using expressed carboxylesterase 1 (CES1) and CES2 bactosomes revealed that dabigatran etexilate was hydrolyzed into BIBR 1087 by CES1 expressed in our Caco-2 cells. Dabigatran 88-108 carboxylesterase 1 Homo sapiens 142-146 24212377-5 2014 The impact of CES1-mediated BIBR 1087 formation during transcellular transport experiments was assessed by comparing several combinations of three experimental approaches: radioactivity detection using [(14)C]dabigatran etexilate as substrate, liquid chromatography-tandem mass spectrometry (LC-MS/MS) quantification of dabigatran etexilate, and in the presence and absence of a CES inhibitor bis(p-nitrophenyl) phosphate (BNPP). Dabigatran 209-219 carboxylesterase 1 Homo sapiens 14-18 24212377-5 2014 The impact of CES1-mediated BIBR 1087 formation during transcellular transport experiments was assessed by comparing several combinations of three experimental approaches: radioactivity detection using [(14)C]dabigatran etexilate as substrate, liquid chromatography-tandem mass spectrometry (LC-MS/MS) quantification of dabigatran etexilate, and in the presence and absence of a CES inhibitor bis(p-nitrophenyl) phosphate (BNPP). Dabigatran 209-229 carboxylesterase 1 Homo sapiens 14-18 24212379-3 2014 The kinetics of DABE hydrolysis in two human recombinant carboxylesterase enzymes (CES1 and CES2) and in human intestinal microsomes and human liver S9 fractions were determined. Dabigatran 16-20 carboxylesterase 1 Homo sapiens 83-87 24212379-6 2014 The ethyl ester of DABE was hydrolyzed exclusively by CES1 to M1 (Km 24.9 +- 2.9 muM, Vmax 676 +- 26 pmol/min per milligram protein) and the carbamate ester of DABE was exclusively hydrolyzed by CES2 to M2 (Km 5.5 +- 0.8 muM; Vmax 71.1 +- 2.4 pmol/min per milligram protein). Dabigatran 19-23 carboxylesterase 1 Homo sapiens 54-58 24212379-6 2014 The ethyl ester of DABE was hydrolyzed exclusively by CES1 to M1 (Km 24.9 +- 2.9 muM, Vmax 676 +- 26 pmol/min per milligram protein) and the carbamate ester of DABE was exclusively hydrolyzed by CES2 to M2 (Km 5.5 +- 0.8 muM; Vmax 71.1 +- 2.4 pmol/min per milligram protein). Dabigatran 160-164 carboxylesterase 1 Homo sapiens 54-58 24212379-8 2014 These results suggest that after oral administration of DABE to humans, DABE is hydrolyzed by intestinal CES2 to the intermediate M2 metabolite followed by hydrolysis of M2 to DAB in the liver by CES1. Dabigatran 56-60 carboxylesterase 1 Homo sapiens 196-200 24212379-8 2014 These results suggest that after oral administration of DABE to humans, DABE is hydrolyzed by intestinal CES2 to the intermediate M2 metabolite followed by hydrolysis of M2 to DAB in the liver by CES1. Dabigatran 72-76 carboxylesterase 1 Homo sapiens 196-200 24212379-8 2014 These results suggest that after oral administration of DABE to humans, DABE is hydrolyzed by intestinal CES2 to the intermediate M2 metabolite followed by hydrolysis of M2 to DAB in the liver by CES1. Dabigatran 56-59 carboxylesterase 1 Homo sapiens 196-200 23467860-8 2013 CONCLUSIONS: Genome-wide association analysis identified that carriage of the CES1 rs2244613 minor allele occurred in 32.8% of patients in RE-LY and was associated with lower exposure to active dabigatran metabolite. Dabigatran 194-204 carboxylesterase 1 Homo sapiens 78-82 24988246-3 2014 Polymorphisms of the CES1 gene have been reported to affect the metabolism of dabigatran etexilate, methylphenidate, oseltamivir, imidapril, and clopidogrel, whereas variants of the CES2 gene have been found to affect aspirin and irinotecan. Dabigatran 78-98 carboxylesterase 1 Homo sapiens 21-25 23239178-8 2013 It is noteworthy that CES1 converts DABE to M1 while CES2 mediates the conversion of DABE to M2. Dabigatran 36-40 carboxylesterase 1 Homo sapiens 22-26 23239178-9 2013 M1 and M2 were further metabolized to DAB by CES2 and CES1, respectively. Dabigatran 38-41 carboxylesterase 1 Homo sapiens 54-58